跳至主要内容
临床试验/NCT00391456
NCT00391456已完成不适用

Use of Animal-Assisted Therapy to Decrease Cardiopulmonary Pressures, Neurohormone Levels, and State Anxiety in Patients Hospitalized With Heart Failure

University of California, Los Angeles2 个研究点 分布在 1 个国家目标入组 76 人开始时间: 2001年11月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
76
试验地点
2
主要终点
Blood pressure

研究概览

简要总结

Effects of complementary therapies on heart failure, a leading cause of hospitalization, are unknown. Animal-assisted therapy improves physiological and psychosocial variables in healthy and hypertensive subjects.

The purpose of this study was to determine whether a 12-minute hospital visit with a therapy dog improves hemodynamics, lowers neurohormone levels, and decreases state anxiety in patients hospitalized with heart failure.

详细描述

Context: Effects of complementary therapies on heart failure, a leading cause of hospitalization, are unknown. Animal-assisted therapy improves physiological and psychosocial variables in healthy and hypertensive subjects.

Objectives: To determine whether a 12-minute hospital visit with a therapy dog improves hemodynamics, lowers neurohormone levels, and decreases state anxiety in patients hospitalized with heart failure.

Design, Setting, Participants: A 3-group (volunteer-dog team, volunteer only, and control) randomized repeated-measures experimental design was used in 76 adult patients with advanced heart failure hospitalized between November 2001 and July 2004. Longitudinal analysis was used to model differences among the 3 groups at 3 time points.

Interventions: One group received a 12-minute visit from a volunteer with a therapy dog, another group received a 12-minute visit from a volunteer, and the control group received usual care, at rest. Data were collected at baseline, 8 minutes after the intervention started, and 16 minutes (4 minutes after intervention ended).

Main Outcome Measures: Blood pressure, heart rate, pulmonary artery pressure, pulmonary capillary wedge pressure, right atrial pressure, cardiac index, systemic vascular resistance, plasma levels of epinephrine and norepinephrine, and state anxiety.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • diagnosis of heart failure requiring medical management with an indwelling pulmonary artery catheter
  • age between 18 and 80 years
  • ability to read, write, and speak English
  • mental status: alert and oriented to person, place, and time
  • SVR greater than 1200 dyne · sec · cm-5 at least once within 12 hours from the start of data collection

排除标准

  • SVR less than 1200 dyne · sec · cm-5
  • allergies to dogs
  • immunosuppression, defined as a white blood cell count of less than 4500 cells/mm3
  • infection as determined by an elevated white blood cell count exceeding 11,000 cells/mm3
  • body temperature greater than 38ºC
  • decreased level of consciousness

结局指标

主要结局

Blood pressure

pulmonary artery pressure

heart rate

right atrial pressure

cardiac index

pulmonary capillary wedge pressure

plasma levels of norepinephrine

systemic vascular resistance

plasma levels of epinephrine

state anxiety

次要结局

未报告次要终点

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

已完成
不适用
se of Animal-Assisted Therapy to decrease cardiopulmonary pressures, neurohormone levels, and state anxiety in patients hospitalised with heart failureHeart failureCirculatory System
ISRCTN26749623Pet Care Trust Foundation (USA)76
已完成
1 期
A Study in Healthy Adult Male Participants to Learn the Way Vericiguat is Absorbed With and Without Food When Taken as a Single Dose in Liquid Form Suitable for Children Compared to a 10 Milligram (mg) Tablet That Releases the Active Substance ImmediatelyChildrenHeart Failure
NCT05086952Bayer36
已完成
1 期
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney FunctionRenal ImpairmentCongestive Heart Failure
NCT05599997Bayer32
已完成
1 期
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender DistributionWorsening Chronic Heart FailureChronic Kidney Disease
NCT04908436Bayer33
已完成
1 期
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender DistributionWorsening Chronic Heart FailureDiabetic Nephropathy
NCT04881994Bayer27